P. Grivas

Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.

More than half of patients had high pretreatment tumor PD-L1 expression, and there was no significant association between PD-L1 status and ORR, PFS, or OS with any first-line therapy, although definitive conclusions cannot be made because of the limited sample size.

Rare prostate cancer histologies: detection, characteristics and treatment.

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods

Background Over the past decades, treatment of metastatic urothelial carcinoma (mUC) has been transformed by three backbone therapies: platinum-based chemotherapy (PBC), immune checkpoint inhibitors (ICIs), and antibody-drug conjugates (ADCs), used alone or in combination. Evaluating temporal trends in overall survival...

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

It is shown that metastasis-to-metastasis seeding is the dominant pattern of cancer spread and that increased polyclonal migration predicts poor prognosis, and that post-mortem cell-free DNA captures genomic and transcriptional heterogeneity of the subtypes, which provides a potential strategy for noninvasive assessmen...

Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.

This work developed and clinically validated the System for Enhanced Evaluation of Tumor Cells (SEE-TC), a deep learning approach for scalable, reproducible phenotyping of individual circulating cells that is the first fully automated AI approach to single-cell segmentation and CTC phenotyping.